228 related articles for article (PubMed ID: 16943408)
1. Risks and benefits of celecoxib to prevent recurrent adenomas.
Psaty BM; Potter JD
N Engl J Med; 2006 Aug; 355(9):950-2. PubMed ID: 16943408
[No Abstract] [Full Text] [Related]
2. Celecoxib for the prevention of colorectal adenomatous polyps.
Arber N; Eagle CJ; Spicak J; Rácz I; Dite P; Hajer J; Zavoral M; Lechuga MJ; Gerletti P; Tang J; Rosenstein RB; Macdonald K; Bhadra P; Fowler R; Wittes J; Zauber AG; Solomon SD; Levin B;
N Engl J Med; 2006 Aug; 355(9):885-95. PubMed ID: 16943401
[TBL] [Abstract][Full Text] [Related]
3. Risks and benefits of celecoxib to prevent colorectal adenomas.
Andersohn F; Suissa S; Garbe E
N Engl J Med; 2006 Nov; 355(22):2371; author reply 2371-3. PubMed ID: 17135594
[No Abstract] [Full Text] [Related]
4. Letter by Cen regarding article, "Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas".
Cen YY
Circulation; 2007 Mar; 115(12):e348; author reply e349. PubMed ID: 17389275
[No Abstract] [Full Text] [Related]
5. The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress.
Hawk E; Viner JL
Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):185-7. PubMed ID: 17301246
[No Abstract] [Full Text] [Related]
6. New, long-term insights from the Adenoma Prevention with Celecoxib Trial on a promising but troubled class of drugs.
Dubois RN
Cancer Prev Res (Phila); 2009 Apr; 2(4):285-7. PubMed ID: 19336723
[No Abstract] [Full Text] [Related]
7. Celecoxib for the prevention of sporadic colorectal adenomas.
Bertagnolli MM; Eagle CJ; Zauber AG; Redston M; Solomon SD; Kim K; Tang J; Rosenstein RB; Wittes J; Corle D; Hess TM; Woloj GM; Boisserie F; Anderson WF; Viner JL; Bagheri D; Burn J; Chung DC; Dewar T; Foley TR; Hoffman N; Macrae F; Pruitt RE; Saltzman JR; Salzberg B; Sylwestrowicz T; Gordon GB; Hawk ET;
N Engl J Med; 2006 Aug; 355(9):873-84. PubMed ID: 16943400
[TBL] [Abstract][Full Text] [Related]
8. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
Solomon SD; Pfeffer MA; McMurray JJ; Fowler R; Finn P; Levin B; Eagle C; Hawk E; Lechuga M; Zauber AG; Bertagnolli MM; Arber N; Wittes J;
Circulation; 2006 Sep; 114(10):1028-35. PubMed ID: 16943394
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib and CVS risk--lessons from the APC and PreSAP studies.
Armstrong DJ
Rheumatology (Oxford); 2007 Apr; 46(4):561-2. PubMed ID: 17132690
[No Abstract] [Full Text] [Related]
10. Selective use of selective nonsteroidal anti-inflammatory drugs in inflammatory bowel disease.
Korzenik JR; Podolsky DK
Clin Gastroenterol Hepatol; 2006 Feb; 4(2):157-9. PubMed ID: 16469674
[No Abstract] [Full Text] [Related]
11. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Solomon SD; McMurray JJ; Pfeffer MA; Wittes J; Fowler R; Finn P; Anderson WF; Zauber A; Hawk E; Bertagnolli M;
N Engl J Med; 2005 Mar; 352(11):1071-80. PubMed ID: 15713944
[TBL] [Abstract][Full Text] [Related]
12. Is the demonstration of adenoma reduction with rofecoxib a pyrrhic victory?
Lynch PM
Gastroenterology; 2006 Dec; 131(6):2003-5. PubMed ID: 17188962
[No Abstract] [Full Text] [Related]
13. Does celecoxib use increase the risk of cardiovascular events?
Oviedo JA; Schroy PC
Gastroenterology; 2005 Oct; 129(4):1348-50. PubMed ID: 16230088
[No Abstract] [Full Text] [Related]
14. Balancing the risks and benefits of celecoxib.
Caldwell B; Beasley R; Weatherall M; Metcalfe S
Am J Med; 2007 Jun; 120(6):e17. PubMed ID: 17524734
[No Abstract] [Full Text] [Related]
15. [Non-steroidal anti-inflammatory agents and prevention of colorectal adenomas and carcinomas].
Raskov HH
Ugeskr Laeger; 2006 Jan; 168(4):359-62. PubMed ID: 16436235
[No Abstract] [Full Text] [Related]
16. The COX-2 inhibitors--an update.
Furberg CD
Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896
[No Abstract] [Full Text] [Related]
17. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
[TBL] [Abstract][Full Text] [Related]
18. Clinical Questions #6. Does celecoxib increase cardiovascular risk?
Mayer BJ; Lamfers R; Feldstein DA
WMJ; 2005 Nov; 104(8):15-6. PubMed ID: 16425910
[No Abstract] [Full Text] [Related]
19. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G
J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
[TBL] [Abstract][Full Text] [Related]
20. Arthritis medicines and cardiovascular events--"house of coxibs".
Topol EJ
JAMA; 2005 Jan; 293(3):366-8. PubMed ID: 15623849
[No Abstract] [Full Text] [Related]
[Next] [New Search]
